Results 211 to 220 of about 10,250,216 (364)

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

Integrating clinical genetics in cardiology: Current practices and recommendations for education. [PDF]

open access: yesGenet Med, 2022
Scherr CL   +8 more
europepmc   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

open access: yesMolecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard   +12 more
wiley   +1 more source

Leveraging PCORnet® to Advance Clinical Genetics and the Genomic Learning Health System. [PDF]

open access: yesMed Care
Rothman RL   +8 more
europepmc   +1 more source

Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG)

open access: yesGenetics in Medicine, 2021
C. Rehder   +9 more
semanticscholar   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard   +5 more
wiley   +1 more source

Clinical Genetics of Inherited Arrhythmogenic Disease in the Pediatric Population. [PDF]

open access: yesBiomedicines, 2022
Martínez-Barrios E   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy